Drugs / BNT162a1
last change Apr 2022 re-read 2 minutes ago

BNT162a1

Developed for
respiratory tract infectious disorder · viral infectious disease
Investigated by
BioNTech SE

Trials 1 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04380701 Apr 2020 → Jun 2021 respiratory tract infectious disorder, viral infectious disease BioNTech SE Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BNT162a1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04380701
Route Intramuscular “administered as intramuscular injection.” NCT04380701